Gastroesophageal Junction Adenocarcinoma Clinical Trials in Beijing, Beijing Municipality
11 recruitingBeijing, Beijing Municipality, China
Showing 1–11 of 11 trials
Recruiting
Phase 3
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction AdenocarcinomaMetastatic Gastric Adenocarcinoma
BeOne Medicines351 enrolled85 locationsNCT07043400
Recruiting
Phase 1Phase 2
A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Antengene Biologics Limited132 enrolled30 locationsNCT07327229
Recruiting
Phase 1Phase 2
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Cervical CancerGastric/Gastroesophageal Junction AdenocarcinomaMicrosatellite Stable Colorectal Cancer
Bristol-Myers Squibb949 enrolled48 locationsNCT04895709
Recruiting
Phase 2
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Esophageal AdenocarcinomaGastroesophageal Junction AdenocarcinomaLocally Advanced Unresectable or Metastatic Gastric Adenocarcinoma
AbbVie180 enrolled49 locationsNCT06628310
Recruiting
Phase 3
JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Shanghai Junshi Bioscience Co., Ltd.560 enrolled68 locationsNCT07284134
Recruiting
Phase 3
A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma
Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Innovent Biologics (Suzhou) Co. Ltd.450 enrolled22 locationsNCT06238843
Recruiting
Phase 1
BC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma.
Gastroesophageal Junction AdenocarcinomaAdvanced or Metastatic Gastric Cancer
Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.80 enrolled1 locationNCT06773312
Recruiting
Phase 1
Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells for Gastric/Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction AdenocarcinomaGastric Adenocarcinoma
Peking University12 enrolled1 locationNCT06353152
Recruiting
Phase 2Phase 3
DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
Gastric CancerGastroesophageal Junction Adenocarcinoma
RemeGen Co., Ltd.90 enrolled12 locationsNCT06221748
Recruiting
Phase 2
Camrelizumab Combined With Chemotherapy and Radiotherapy Perioperative Treatment of Esophageal Gastric Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma (Siewert II-III)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences68 enrolled1 locationNCT06163729
Recruiting
Phase 2
Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
Gastric CancerGastroesophageal Junction Adenocarcinoma
RemeGen Co., Ltd.90 enrolled11 locationsNCT06155383